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Sodium diclofenacAbstract The aim of this study was to synthesize and evaluate novel biodegradable polyesters namely;
poly(ethylene glycol)-Poly(glycerol adipate-co-x-pentadecalactone), PEG-PGA-co-PDL-PEG, and
poly(ethylene glycol methyl ether)-Poly(glycerol adipate-co-x-pentadecalactone), PGA-co-PDL-PEG-
me as an alternative sustained release carrier for lung delivery compared with non-PEG containing
polymer PGA-co-PDL. The co-polymers were synthesized through lipase catalysis ring opening poly-
merization reaction and characterized using GPC, FT-IR, 1H-NMR and surface contact angle. Fur-
thermore, microparticles containing a model hydrophilic drug, sodium diclofenac, were prepared via
spray drying from a modiﬁed single emulsion and characterized for their encapsulation efﬁciency, geo-
metrical particle size, zeta potential, tapped density, primary aerodynamic diameter, amorphous nature,
morphology, in vitro release and the aerosolization performance. Microparticles fabricated from
mPEG-co-polymer can be targeted to the lung periphery with an optimum in vitro deposition. Further-
more, a signiﬁcantly higher in vitro release (p> 0.05, ANOVA/Dunnett’s) was observed with the PEG
and mPEG-co-polymers compared to PGA-co-PDL. In addition, these co-polymers have a good safety
proﬁle upon testing on human bronchial epithelial, 16HBE14o- cell lines.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Polymeric microparticles produced using poly(ether anhy-
dride) and poly(lactide-co-glycolide), PLGA, have been inves-
tigated to achieve sustained or controlled release of intended
therapeutic agents to the lungs (Kawashima et al., 1999;
Edwards et al., 1997; Fu et al., 2002; Learoyd et al., 2010; Fie-gel et al., 2004). However, drug incorporation with these carri-
ers is quite low which makes it difﬁcult to encapsulate
sufﬁcient amounts of drugs for efﬁcient therapy (Govender
et al., 1999; Leo et al., 2004). Also PLGA based particles are
typically associated with a burst release which is undesirable
when used as controlled release formulations (Kim and Mar-
tin, 2006). Moreover, the triphasic release pattern is not desir-
able for lung delivery and the acidic environment evolved
during the degradation of PLGA and PLA carriers affects
the stability of loaded macromolecules (Van de Weert et al.,
2000; Batycky et al., 1997). This is partly due to the fact that
PLGA and PLA were not speciﬁcally designed for use in the
lungs. Thus a new polymer which overcomes these problems
is imperative in the formulation of carriers for pulmonary
delivery.
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co-PDL, have proven to be a promising carrier for hydrophilic
(Puri et al., 2008), hydrophobic (Thompson et al., 2007) drugs
as well as macromolecules (Tawfeek et al., 2010). More re-
cently, they were shown to be a useful carrier for lung delivery
(Tawfeek et al., 2011). However, the higher hydrophobicity of
this carrier can greatly affect their lung deposition through
microparticles aggregation, hence limiting their deep deposi-
tion into the alveoli region as well as its in vitro release pattern.
Additionally, the hydrophobic nature of the produced PGA-
co-PDL microparticles, and their size make them undergo ra-
pid phagocytosis by antigen-presenting cells (APC) like macro-
phages and dendritic cells (Ahsan et al., 2002; Foged et al.,
2005; Thiele et al., 2001) which limits their residence in the
lung airways. Additionally, the lower encapsulation efﬁciency
which was recorded previously in the preparation of sodium
ﬂuorescein (a model hydrophilic drug) loaded PGA-co-PDL
microparticles was an issue in drug delivery (Tawfeek et al.,
2011). One of the most important approaches to obtain micro-
particles, becoming repellent to the adsorption of asponic pro-
teins and resistant to unspeciﬁc phagocytosis, relies on
polymer PEGylation (Donald et al., 2006). The purpose of
these PEG chains is to create a barrier layer to block the adhe-
sion of asponins present in blood serum, so that the particles
can remain camouﬂaged or invisible to phagocyotic cells.
PEG is an uncharged, hydrophilic polymer, which is soluble
in water as well as in many organic solvents. Due to its low
toxicity and immunogenicity, PEG is highly suitable for bio-
medical applications (Harris and Zalipsky, 2004; Bentley
et al., 2005; Harris and Chess, 2003). PEGylation can also pro-
mote pulmonary delivery to achieve long-lasting peptide ef-
fects (Onoue et al., 2008; Youn et al., 2008). BioAir
(Biosante Pharma, USA) comprises calcium phosphate nano-
particulates (CaP) of insulin, and CaP–PEG particles signiﬁ-
cantly reduced the elimination of insulin in rats following
pulmonary administration. Consequently, the amount of bio-
available insulin from this pulmonary formulation was equiv-
alent to or higher than that of insulin injected subcutaneously
(Garcia-Contreras et al., 2003).
PEG was incorporated into the polymer backbone to re-
duce the interparticle adhesion forces and decrease the density
of polymer aerosols, as well as to render the particles less sus-
ceptible to phagocytosis (Gref et al., 1994). Recently, PEGylat-
ed poly(lactic-co-glycolic acid) (PEG-PLGA) has been
reported as carriers for both hydrophobic and hydrophilic
drugs (Dorati et al., 2005; Cheng et al., 2007). Furthermore,
PEG can increase the polymer hydrophilicity as well as its deg-
radation proﬁle which is suitable for lung delivery (Fu et al.,
2002). Fiegel et al. (2004) studied the incorporation of different
concentrations of PEG to poly(sebacic acid) to form poly
(ether-anhydride) for dry powder aerosol inhalation. The
authors found that addition of 10% PEG to the polymer back-
bone signiﬁcantly enhanced the deposition in the lower stages
of an in vitro lung model following aerosolization from the
DPI. Moreover, it has the ability to avoid the phagocytic clear-
ance and provide a controlled release of bovine serum albumin
for prolonged pulmonary delivery. Nowadays, using function-
alized PEG enables researchers to change the polymer proper-
ties by exploiting the functional groups for attaching, cross
linking and conjugation with various chemical moieties. The
terminal hydroxyl group of PEG can react either by chemical
catalysis (Dong and Feng, 2004; Zhou et al., 2004), enzyme/lipase catalysis (Kumar et al., 2002; He et al., 2003) or through
catalyst free synthesis to form a part of a polyester backbone
(Lin et al., 2005).
The aim of this work was to study the modiﬁcation of PGA-
co-PDL backbone through incorporation of either poly(ethyl-
ene glycol), PEG, or poly(ethylene glycol methyl ether), mPEG,
into the PGA-co-PDL backbone. The polymerization process
was proceeded utilizing the terminal hydroxyl groups of PEG
or mPEG with monomers namely, glycerol, divinyl adipate
and pentadecalactone through lipase catalysis. Then, micropar-
ticles were prepared using either PEG-PGA-co-PDL-PEG or
PGA-co-PDL-PEGme via spray drying the modiﬁed single
emulsion (o/w) incorporating sodium diclofenac (SD) as a mod-
el hydrophilic drug. The prepared microparticles were evaluated
for their spray drying yield, encapsulation efﬁciency, particle
size, zeta potential, tapped density, theoretical primary aerody-
namic diameter (dae), morphology and in vitro release in phos-
phate buffered saline of pH 7.4. Moreover, Percentage ﬁne
particle fraction, %FPF, ﬁne particle dose, FPD, and mean
median aerodynamic diameter, MMAD, for the dry powder
inhalation microparticles, were calculated from impaction study
using the Next Generation Impactor, NGI (ﬂow rate 60 L/min,
HandiHaler). Cell viability study was also performed using
human bronchial epithelium cell lines ‘‘16HBE14o’’ for PEG-
PGA-co-PDL-PEG, PGA-co-PDL-PEGme in comparison with
microparticles fabricated from PGA-co-PDL.2. Materials and methods
2.1. Materials
Glycerol, x-pentadecalactone, Poly(ethylene glycol) (PEG,
Mw 4500Da), Poly(ethylene glycol methyl ether) (mPEG,
Mw 2000Da), Novozyme 435 (a lipase from Candida antarctica
immobilized on a microporous acrylic resin), poly(vinyl alco-
hol) (PVA, MW 9–10 K, 80%), L-leucine, RPMI-1640 medium
with L-glutamine and sodium hydrogen carbonate (NaHCO3),
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), sodium diclofenac were all obtained from Sigma–Al-
drich, UK. Dichloromethane (DCM) and Methanol were pur-
chased from BDH laboratory supplies, UK. Tetrahydrofuran
(THF), 75 cm2/tissue culture ﬂask with vented cap (IWAKI
brand), 24 tissue culture test plates, 96 well ﬂat bottom plates,
Antibiotic/Antimycotic Solution (100X) were purchased from
Fisher Scientiﬁc, UK. Phosphate buffered saline tablets
(PBS), pH 7.4, were obtained from Oxoid, UK. Divinyl
adipate was obtained from Fluorochem, UK. Fetal Calf Serum
heat inactivated was purchased from Biosera, UK. 16HBE14o-
cells were produced by Dr. Dieter Gruenert from the
California Paciﬁc Medical Center, University of California
San Francisco, USA.
2.2. Polymer synthesis
The PEG and mPEG co-polymers, PEG-PGA-co-PDL-PEG
and PGA-co-PDL-PEGme, were synthesized using the enzyme
catalyzed polycondensation and ring opening co-polymeriza-
tion reactions as described previously (Thompson et al.,
2006) with slight modiﬁcation. Brieﬂy, PEG (4500Da) or
mPEG (2000Da) was added to the reaction medium (Tetrahy-
drofuran,THF) incorporating monomers (glycerol, divinyl
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435 (1 g). The theoretical molar ratio of PEG or mPEG: glyc-
erol: divinyl adipate: -pentadecalactone was 0.005:1:1:1.
Approximately 0.0006 M, 2.6 g of PEG and 0.00025 M, 0.5 g
of mPEG were added to 0.05 M of each monomer. The synthe-
sized co-polymer was characterized by gel permeation chroma-
tography, GPC (Viscotek TDA Model 300 using OmniSEC3
operating software), calibrated with polystyrene standards
(polystyrene standards kit, Supelco, USA). FT-IR spectrum
was obtained using a Perkin Elmer Spectrum BX spectrometer
ﬁtted with a PIKE technologies MIRacle sampling accessory
and using Spectrum v5.0.1 for data processing, and 1H-
NMR spectroscopy (Bruker AVANCE 300, Inverse probe
with B-ACS 60, Auto sampler with gradient chemming) as de-
scribed by Thompson et al. (2006). Additionally the degree of
hydrophilicity was determined through measuring the surface
contact angle (h). A very small drop of water (6–10 lL) was
dropped on the polymer ﬁlm sample via pre-calibrated syringe
needle. Photographs of dropping water droplet were taken un-
til the droplet stabilized on the surface via a built-in digital
camera at 16 ms frame interval for 60 ms using Attension
(Theta Lite, CAM-101) by KSV instruments. Then, the surface
contact angle (h) was measured using the circular model of the
drop proﬁle ﬁtting method applied to these images.2.3. Microparticle preparation
Microparticles were prepared by spray drying directly from a
modiﬁed single emulsion (o/w). Brieﬂy, 50 mg SD was dis-
solved in the organic phase, composed of 2.5 ml methanol
and 7.5 ml DCM (1:3 ratio), containing 450 mg polymer fol-
lowed by addition to an aqueous phase, 150 ml distilled water
containing 1% w/v PVA as an emulsiﬁer and L-leucine (1.5%
w/w of polymer weight) as a dispersing agent, under moderate
stirring conditions (Silverson L5RT mixer, 2000 rpm at room
temperature, 25 C) to form the o/w single emulsion. The pro-
duced single emulsion was then spray dried using a mini-spray
dryer (Bu¨chi, B-290 Flawil, Switzerland). Spray drying condi-
tions were performed as previously reported (Tawfeek et al.,
2011). The spray drying parameters were set to preserve the
outlet temperature in the range of 44–48 C, as DSC analysis
indicated a low melting point for PEG-PGA-co-PDL-PEG
and PGA-co-PDL-PEGme.
2.4. Microparticles characterization
2.4.1. Yield, drug loading and encapsulation efﬁciency
The yields of spray dried PGA-co-PDL, PEG-PGA-co-PDL-
PEG and PGA-co-PDL-PEGme microparticles were quanti-
ﬁed as the percentage mass of anticipated total powder yields.
The drug loading (DL) and percentage encapsulation efﬁciency
(EE%) were calculated using Eqs. (1) and (2), respectively:
DL ¼Weight of SD in microparticles
Microparticles sample weight
ð1Þ
EEð%Þ ¼ Actual weight of SD in sample
Theoritical weight of SD
 
 100 ð2Þ
Brieﬂy, 10 mg of the microparticles was weighed and solubi-
lized in DCM/water mixture (2:1, 8:4 ml of DCM: water) to
dissolve the polymer and extract the drug. The amount ofwater added has the ability to dissolve SD either encapsulated
or present on the surface of microparticles as the solubility of
SD in water reported to be 14.18 mg/ml (Maja et al., 2004).
The two phases were then separated by centrifugation (5 min
at 16200g, accuSpin Micro 17) and the aqueous layer analyzed
for SD content spectrophotometrically at 275.5 nm (n= 3).
2.4.2. Particle size, zeta potential, powder density and primary
aerodynamic diameter (dae)
Spray dried microparticles were sized using a Zetaplus, Brookha-
ven Instruments, UK. Microparticles suspension (100 ll) was di-
luted to 4 ml using double distilled water and the measurements
recorded at 25 C (n= 3). The zeta potential was determined
using the same instrument with 50 ll of the suspension added
to 2 ml of distilled water and the measurement was performed
using a gold-plated zeta dip probe at 25 C (n= 3). The poured
density of spray-dried microparticle powders was determined by
adding approximately 0.5 g of powder to a 10 ml graduated cyl-
inder and recording the volume. The tapped density was deter-
mined by tapped density measurements on the same samples
in a 10 ml graduated measuring cylinder until constant volume
was obtained (Grenha et al., 2005) (n= 3). dae was calculated
using data acquired from geometric particle size (d) and tapped
density (p) according to (Eq. (3)) (Bosquillon et al., 2004).
dae ¼ d
ﬃﬃﬃﬃﬃ
q
q1
r
q1 ¼ 1 g=cm3 ð3Þ2.4.3. Amorphous nature and water content
The degree of amorphous material from the spray dried formu-
lations was performed using differential scanning calorimetry
(DSC, Perkin Elmer Pyris 1). Brieﬂy, 3–5 mg of sample was
placed into a hermetically sealed and crimped pan. The samples
were subjected to two scanning programs in the DSC using a
heating rate of 20 C/min purged with nitrogen at 20 ml/min
as described previously by Thompson et al. (2007). The weight
loss of the powders as a function of temperature was determined
using a thermogravimetric analyzer (TGA 2050-Thermogravi-
metric analyzer, UK). Approximately 6–8 mg of each sample
was weighed in a platinum pan and heated at the temperature
range of 25–260 C using a scanning rate of 10 C/min purged
under nitrogen at 20 ml/min (n= 3).
2.4.4. Particle morphology
Microparticles were visualized by scanning electron micros-
copy (FEI – Inspect S Low VAC Scanning Electron Micro-
scope). Brieﬂy, particles were mounted on aluminum stubs
(pin stubs, 13 mm) layered with a sticky conductive carbon
tab and air dried. An atomic layer of gold (10–15 nm) was
deposited onto the particle containing stubs using an EmiTech
K 550X Gold Sputter Coater, 25 mA for 3 min.
2.5. In-vitro release
Approximately, 10 mg of spray dried microparticles was added
to 1.5 ml microtubes, containing 1 ml phosphate buffer saline
pH 7.4 under sink conditions (Maja et al., 2004), and incubated
at 37 C on an orbital shaker (IKA KS 130) at 250 rpm (n= 3).
The supernatants were collected to quantify the release of SD
over 24 h by centrifugation (5 min at 13500 rpm, accuSpinMicro
17) and analyzed spectrophotometrically as above.
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Aerodynamic particle size distribution was determined using
NGI. Microparticle samples (20 ± 0.4 mg) were manually
loaded into hydroxypropyl methylcellulose capsules (HPMC
size 3) and placed in a HandiHaler. A pump (Copley Scien-
tiﬁc, Nottingham, UK) was operated at a ﬂow rate of 60 L/min
for 4 s and the NGI plates were coated with 1% w/w glycerol/
methanol solution. Following inhalation all parts of NGI were
washed with DCM/water (2:1), and analyzed as above. The
%FPF (deﬁned as the mass of drug deposited (dae < 4.6 lm),
expressed as a percentage of the emitted dose), MMAD (Fed-
dah et al., 2000), and the FPD (expressed as the mass of drug
deposited in the NGI (dae < 4.6 lm), were determined (n= 3).
2.7. Cell viability study
The toxicity proﬁles of the prepared formulations compared
with non-PEGylated PGA-co-PDL microparticles (0–5 mg/
ml) were evaluated over 24 h in the normal human bronchial
epithelial (16HBE14o-) cell line (passage no. 22) as previously
reported (Tawfeek et al., 2011). The relative cell viability (%)
was calculated as presented in Eq (4):
Viabilityð%Þ ¼ A S
CM S 100 ð4Þ
where A is the absorbance of the test substance concentrations,
S is the absorbance obtained for the (isopropanol) and CM is
the absorbance obtained for untreated cells incubated with
medium (control).
2.8. Statistical analysis
The formulations were compared with each other by means of
a one-way ANOVA with Tukey’s and Dunnett multiple com-
parison tests assuming an equal variance or with Dunnett’s C
test assuming non-equal variance. The statistical signiﬁcance
level was set at p 6 0.05.
3. Results
3.1. Polymer synthesis and characterization
The chemical structure of PEG-PGA-co-PDL-PEG and PGA-
co-PDL-PEGme co-polymers is presented in (Fig. 1a and b,
respectively).Figure 1 Chemical structure of (a) PEG-PGAThe random nature of the co-polymers was conﬁrmed from
the integration pattern of peaks obtained from 1H-NMR spec-
tra. PEG-PGA-co-PDL-PEG; 1H-NMR (dH CDCl3,
300 MHz): 1.26 (s, 21.7H, H-g), 1.59 (m)-1.68 (m) (8.2H, H-
e, e’, h), 2.26 (m)-2.38 (m) (6H, H-d, d’, i), 3.64 (s, 3.9H, H-
j, k, l), 4.03 (m)-4.17 (m) (6H, H-a, b, c, f), 5.1 (s, H, H-m).
PGA-co-PDL-PEGme; 1H-NMR (dH CDCl3, 300 MHz):
1.26 (s, 21.0H, H-g), 1.57 (m)-1.67 (m) (8.0H, H-e, e’, h),
2.26 (m)-2.39 (m) (6H, H-d, d’, i), 3,38 (s, 4H, H-l), 3.68 (s,
2.5H, H-j, k, l), 4.03 (m)-4.34 (m) (5H, H-a, b, c, f), 5.1 (s,
H, H-m). In addition, the co-polymers had the following char-
acteristic FT-IR bands at t max: typical broad shallow –OH
band appeared at 3447.0 cm1, –CH2 groups of DVA, PDL,
PEG and mPEG appeared at 2915.7 cm1, –CH group of glyc-
erol appeared at 2848.4 cm1, –CH3 group of methyl ether
symmetric bending vibration appeared at 1365.7 cm1, the car-
bonyl group of DVA and lactone monomers appeared at
1730.7 cm1, C–O group of lactone, glycerol and PEG ap-
peared at 1417.0 and 1164.8 cm1, respectively. Furthermore,
data from GPC conﬁrmed unimodal mass distribution with
no peaks related to free PEG or mPEG. The calculated co-
polymers’ Mws were found to be 21.0, 13.6 and 7.6 KDa cor-
responding to PGA-co-PDL, PEG-PGA-co-PDL-PEG and
PGA-co-PDL-PEGme, respectively as shown in Fig. 2.
The actual co-polymer ratios were found to be (1:1:1:0.01
and 1:1:1:0.017) for PEG-PGA-co-PDL-PEG and PGA-co-
PDL-PEGme, respectively with PEG and mPEG content
9.05% and 11.64%, calculated from the ratios of PEG, mPEG
Mwt and the total co-polymer Mwt. In addition, the surface
contact angle (h) was found to be 70.02 ± 0.1, 48.17 ± 0.7
and 49.63 ± 1.3 for PGA-co-PDL, PEG-PGA-co-PDL-PEG
and PGA-co-PDL-PEGme, respectively.
3.2. Microparticle preparation and characterization
Spray drying from a modiﬁed single emulsion produced micro-
particles with a high yield of 70.23 ± 2.5% and 75.14 ± 3.6%,
SD loading of 67.64 ± 3.6 and 66.84 ± 2.7 lg/mg particle and
encapsulation efﬁciency 60.88 ± 3.3% and 60.16 ± 2.5% for
PEG-PGA-co-PDL and PGA-co-PDL-PEGme, respectively
(Table 1). In addition, all formulations had a geometrical par-
ticle size less than 4.0 lm suitable for targeting the respiratory
bronchioles (Table 1). Moreover, the prepared microparticles
had a higher negative surface charge indicating a greater
degree of colloidal stability within the dispersion medium
(Table 1). The tapped densities for all formulations ranged
from 0.24 ± 0.2–0.26 ± 0.2 g/cm3, Table 1 and were used-co-PDL-PEG & (b) PGA-co-PDL-PEGme.
Figure 2 Gel permeation chromotrgrams for PGA-co-PDL, PEG-PGA-co-PDL-PEG and PGA-co-PDL-PEGme.
Table 1 Physical characteristics of spray dried microparticles. The results are the mean ± S.D.
Formulation Yield (%) Drug loading
(lg/mg
polymer)
EE (%) Particle size (lm) Zeta
potential
(mv)
Tapped
density
(g/cm3)
dae(lm) Water
content
(%)
PGA-co-PDL 68.88 ± 5.5 76.52 ± 2.6 68.87 ± 9.0 2.30 ± 0.18 32.28 ± 2.6 0.26 ± 0.2 1.17 ± 0.31 2.56 ± 0.2
PEG-PGA-co-PDL 70.23 ± 2.5 67.64 ± 3.6 60.88 ± 3.3 3.92 ± 0.12 29.98 ± 1.4 0.25 ± 0.3 1.96 ± 0.15 1.48 ± 0.4
PGA-co-PDL-PEGme 75.14 ± 3.6 66.84 ± 2.7 60.16 ± 2.5 2.57 ± 0.23 31.26 ± 1.8 0.24 ± 0.2 1.25 ± 0.42 3.56 ± 0.7
Yield, drug loading, encapsulation efﬁciency (n= 6). Particles size, zeta potential, tapped density, primary aerodynamic diameter and water
content (n= 3).
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oretical aerodynamic diameter (dae). As shown in (Table 1), the
calculated dae was between (1.17 ± 0.31 and 1.25 ± 0.42 lm).
The water contents for all formulations were within the range
of moisture contents of spray dried powders as reported previ-
ously (Sta˚hl et al., 2002; Chew et al., 2005a).
Fig. 3 represents the DSC thermograms of PEG-PGA-co-
PDL-PEG, PGA-co-PDL-PEGme co-polymers (control) and
PEG-PGA-co-PDL-PEG, PGA-co-PDL-PEGme spray dried
microparticles loaded with SD. The outlet temperature on the
spray dryer was adjusted to be between 45 and 48 C due to
the low melting of the co-polymer as noted in the DSC thermo-
grams (Fig. 3). It is worth noting that the spray drying process
changed the thermal behaviors of the blank polymers, resulting
in a lower onset of melting, 58.32 C (PEG-PGA-co-PDL-PEG)
and 56.45 C (PGA-co-PDL-PEGme) compared to 60.53 C
and 60.12 C for the co-polymers alone (control). In addition,
the endothermic peaks became broader in shape with spray
dried formulations coupled with a decrease in area under the
endothermic curve and the heat of fusion (DH) 2.54 J/g and
1.88 J/g for PEG-PGA-co-PDL-PEG and PGA-co-PDL-PEG-
me formulations, respectively (Fig. 3).
Scanning electron microscopy, SEM, showed spherical par-
ticles with wrinkled morphology for all the investigated spray
dried microparticles (Fig. 4, a, b and c, PGA-co-PDL, PEG-
PGA-co-PDL-PEG and PGA-co-PDL-PEGme, respectively).
Furthermore, the prepared microparticles appeared to be de-
formed with some aggregation and there is no observed differ-
ence between the produced spray dried microparticles using
PGA-co-PDL or the PEG, mPEG co-polymers.3.3. In vitro release
The release of SD from spray dried microparticles prepared
from different co-polymers is presented in Fig. 5. Basically the
release proﬁle was characterized with a higher initial burst
release phase, especially with PEG and mPEG co-polymers, fol-
lowed by a sustained released phase till 24 h. A non-signiﬁcant
(p> 0.05, ANOVA/Tukey’s) higher release was found with
PGA-co-PDL-PEGme compared to PEG-PGA-co-PDL-PEG
94.64 ± 1.2% and 87.83 ± 4.4%, respectively after 24 h release
in PBS buffered saline at 37 C. Furthermore, microparticles
prepared using PGA-co-PDL showed a signiﬁcant (p< 0.05,
ANOVA/Dunnett’s C) lower burst and continuous release
29.80 ± 6.1% and 74.65 ± 6.3%, respectively compared to
PEG-PGA-co-PDL-PEG 42.55 ± 2.7%, 87.83 ± 4.4% and
PGA-co-PDL-PEGme 50.47 ± 1.7%, 94.64 ± 1.2%. More-
over, by analyzing the release data of SD, from different micro-
particle formulations, in different release kinetic models namely;
Zero, First and Higuchi diffusion models, it was found that the
best model ﬁt was according to the Higuchi diffusion model
with the highest R2 value of 0.931, 0.859 and 0.929 and the re-
lease rate constant, Kh = 7.302, 7.231 and 6.890 mg/cm
2 min1/2
for PGA-co-PDL, PEG-PGA-co-PDL-PEG and PGA-co-PDL-
PEGme, respectively.3.4. In-vitro aerosolization performance
SD deposition data, obtained from spray dried formulations,
indicated there was a difference in aerosolization performance
Figure 3 DSC thermograms for (A) PEG-PGA-co-PDL-PEG, (B) PGA-co-PDL-PEGme, (C) PEG-PGA-co-PDL-PEG spray dried
microparticles with 1.5% w/w L-leucine and (D) PGA-co-PDL-PEGme spray dried microparticles with 1.5% w/w L-leucine.
Figure 4 Scan electron micrographs comparing (a) PGA-co-PDL (b) PEG-PGA-co-PDL-PEG and (c) PGA-co-PDL-PEGme spray
dried microparticles. The scale bar represents 5 lm.
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Figure 5 Cumulative in vitro release of sodium diclofenac from
spray dried microparticles in PBS buffer at 37 C. Data represents
mean ± S.D. (n= 3).
Figure 6 Comparison of sodium diclofenac deposition in cap-
sule, inhaler, mouth piece and throat via different formulations.
Data represents mean ± S.D. (n= 3). *p< 0.05 (capsule) PGA-
co-PDL and PEG-PGA-co-PDL-PEG compared to PGA-co-
PDL-PEGme (ANOVA/Tukey’s).
Figure 7 Comparison of sodium diclofenac deposition in differ-
ent stages of NGI, (Cut-off diameter, 7.8–0.13 lm) for different
formulations. Data represents mean ± S.D. (n= 3). *p< 0.05
(stages 1, 2 and 4) PGA-co-PDL-PEGme compared to PGA-co-
PDL and PEG-PGA-co-PDL-PEG (ANOVA/Tukey’s). *p< 0.05
(stages 6 and 7) PGA-co-PDL-PEGme comapred to PGA-co-PDL
(ANOVA/Tukey’s, Dunnett C). *p< 0.05 (stage 8) PEG-PGA-co-
PDL-PEG and PGA-co-PDL-PEGme compared to PGA-co-PDL
(ANOVA/Tukey’s).
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and 7). For example, PGA-co-PDL and PEG-PGA-co-PDL-
PEG showed a signiﬁcantly higher powder deposit in the
capsule compared with PGA-co-PDL-PEGme (p< 0.05,
ANOVA/Tukey’s, Fig. 6). At the same time, there were no
signiﬁcant differences between different carriers (co-
polymers) in the amount of powder deposited in the inhaler,
mouth piece and throat (p> 0.05, ANOVA/Tukey’s,
Dunnett’s C, Fig. 6).
Regarding the SD deposition in different stages of NGI,
signiﬁcantly higher amounts of PGA-co-PDL-PEGme micro-
particles were deposited in stages 1 and 2, (Cut-off diameter,
7.8 and 4.6 lm), compared to PGA-co-PDL and PEG-PGA-
co-PDL-PEG fabricated microparticles (p< 0.05, ANOVA/
Tukey’s, Fig. 7). At the same time, there was no signiﬁcant dif-
ference between PGA-co-PDL and PEG-PGA-co-PDL-PEG
formulations (p> 0.05, ANOVA/Tukey’s, Dunnett’s C,
Fig. 7). Furthermore, there were no signiﬁcant differences be-
tween all investigated carriers on the amount of microparticlesdeposited on stage 3 and stage 5 (Cut-off diameter, 2.7,
0.96 lm, p> 0.05, ANOVA/Tukey’s, Dunnett’s C, Fig. 7).
However, on stage 4, (Cut-off diameter, 1.6 lm), signiﬁcantly
higher amounts of PGA-co-PDL-PEGme microparticles were
deposited compared to PGA-co-PDL and PEG-PGA-co-
PDL-PEG microparticles (p< 0.05, ANOVA/Tukey’s,
Fig. 7).
In lower stages 6 and 7 (Cut-off diameter, 0.57 and
0.33 lm), it was found that, PGA-co-PDL-PEGme showed a
signiﬁcantly higher deposition compared to PGA-co-PDL
microparticles (p< 0.05, ANOVA/Tukey’s, Dunnett’s C,
Fig. 7) with no signiﬁcant difference between PGA-co-PDL-
PEGme and PEG-PGA-co-PDL-PEG. Furthermore, there
was no signiﬁcant difference between PGA-co-PDL and
PEG-PGA-co-PDL-PEG microparticles deposited on those
stages (p> 0.05, ANOVA/Tukey’s, Dunnett’s C, Fig. 7).
PEG-PGA-co-PDL-PEG and PGA-co-PDL-PEGme showed
signiﬁcantly higher amounts of microparticles deposited on
MOC, stage 8 (Cut-off diameter, 0.13 lm), compared to
PGA-co-PDL microparticles (p< 0.05, ANOVA/Tukey’s,
Fig. 7). Moreover, there is no signiﬁcant difference between
PEG-PGA-co-PDL-PEG and PGA-co-PDL-PEGme fabri-
cated microparticles (p> 0.05, ANOVA/Tukey’s, Dunnett’s
C, Fig. 7).
Higher FPD and FPF (%) were obtained using PEG-PGA-
co-PDL-PEG and PGA-co-PDL-PEGme compared to PGA-
co-PDL microparticles as shown in (Table 2) being only
signiﬁcant with PGA-co-PDL-PEGme compared to the other
carriers (p< 0.05, ANOVA/Tukey’s). The MMAD obtained
from cascade impaction studies ranged from (4.58 ± 0.7 to
2.92 ± 0.1 lm, Table 2) indicating particle aggregation
(duplicate) compared to geometric particle size (Table 1).
Furthermore, PGA-co-PDL-PEGme microparticles showed a
signiﬁcantly lower MMAD value compared to PGA-co-PDL
microparticles (Table 2, p< 0.05, ANOVA/Tukey’s).
Table 2 Percentage ﬁne particle fraction (FPF%), ﬁne parti-
cle dose (FPD, lg) and mean median aerodynamic diameter
(MMAD, lm) for sodium diclofenac loaded microparticles
formulations. The results are the mean ± S.D.
Formulation FPF% FPD (lg) MMAD (lm)
PGA-co-PDL 30.73 ± 3.8 20.89 ± 3.2 4.58 ± 0.77
PEG-PGA-co-PDL 34.07 ± 5.4 25.81 ± 7.0 4.36 ± 0.75
PGA-co-PDL-PEGme *44.06 ± 1.8 **33.93 ± 0.58 ***2.92 ± 0.17
* p> 0.05 (FPF%) PGA-co-PDL-PEGme compared to PGA-co-
PDL, PEG-PGA-co-PDL-PEG (ANOVA/Tukey’s).
** p> 0.05 (FPD) PGA-co-PDL-PEGme compared to PGA-co-
PDL, PEG-PGA-co-PDL-PEG (ANOVA/Tukey’s).
*** p> 0.05 (MMAD) PGA-co-PDL-PEGme compared to PGA-
co-PDL (ANOVA/Tukey’s).
Figure 8 Cell viability of human bronchial epithelium cell line
(16HBE14o) measured by MTT cytotoxicity assay following 24 h
exposure to different concentrations of PGA-co-PDL, PEG-PGA-
co-PDL-PEG and PGA-co-PDL-PEGme microparticles suspen-
sion. Data represent mean ± S.D., (n= 6).
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The investigated co-polymer microparticles appear to be well
tolerated by normal lung bronchial epithelial cells in vitro.
Higher percentage cell viability was observed (88.14 ±
14.0%, 96.07 ± 5.2% and 89.27 ± 8.5% for PGA-co-PDL,
PEG-PGA-co-PDL-PEG and PGA-co-PDL-PEGme, respec-
tively) even at higher microparticle concentrations of 5 mg/
ml. Moreover, there was no signiﬁcant difference between
PGA-co-PDL and PEG or mPEG containing PGA-co-PDL
polymer in the percentage of cell viability (p> 0.05, ANO-
VA/Tukey’s, Dunnett’s C, Fig. 8).
4. Discussion
Recently, Poly(glycerol adipate-co-x-pentadecalactone), PGA-
co-PDL, a biodegradable polyester, was studied as a promising
new sustained release carrier for lung delivery (Tawfeek et al.,
2011). However, its higher hydrophobicity is still an issue
which limits its residence in the lung, release proﬁle and depo-
sition to alveoli region. In this study we are trying to solve
these problems through modiﬁcation of the PGA-co-PDLbackbone via introduction of poly(ethylene glycol), PEG
4500Da, or poly(ethylene glycol methyl ether) mPEG
2000Da. This modiﬁcation can be performed via lipase cata-
lyzed ring opening polymerization and polycondensation reac-
tion as the method described previously (Thompson et al.,
2006). Lipase from Candida antarctica efﬁciently produced
PEG-PGA-co-PDL-PEG and PGA-co-PDL-PEGme co-poly-
mers within high yield reaching 12–15 g.
The lower Mwt of PGA-co-PDL-PEGme, 7.5 KDa, could
be attributed to the mode of attachment of mPEG into the
PGA-co-PDL. mPEG is attached to the PGA-co-PDL on its
side chains and after certain polymer growth, mPEG blocks
the terminal positions and there is no possibility for further
attachment of monomers hence, the chain stopped and the
polymerization reaction was terminated. However, in case of
PEG-PGA-co-PDL-PEG, PEG molecules can attach to
PGA-co-PDL backbone in different positions. They can attach
to DVA or PDL subunits, hence being incorporated inside the
polymer chain and this cannot impede the chain progress
which leads to a higher co-polymer Mwt (13.6 KDa) compared
to PGA-co-PDL-PEGme (7.5 KDa). Furthermore, PEG-
PGA-co-PDL-PEG and PGA-co-PDL-PEGme had 9.05%
and 11.5% PEG and mPEG contents which are suitable for
drug delivery applications for PEG-containing polymers. In
addition the higher mPEG content compared to PEG could
be attributed to the higher feed ratio (1:1:1:0.017, 1:1:1:0.01
for PGA-co-PDL-PEGme and PEG-PGA-co-PDL-PEG,
respectively). The incorporation of either PEG or mPEG leads
to a signiﬁcant reduction on the surface contact angle of both
PEG-PGA-co-PDL-PEG and PGA-co-PDL-PEGme com-
pared to PGA-co-PDL and thus being reversed on the polymer
hydrophilicity as well as its in vitro deposition.
The method of w/o/w multiple emulsion solvent evapora-
tion is considered as the most widely used method for encapsu-
lation of hydrophilic compounds. However, the diffusion and
partitioning of such compounds to the external aqueous phase
limit its encapsulation and loading (Uchida et al., 1997). In this
study, we have tried to enhance the encapsulation of SD, a
hydrophilic molecule, by making a co-solvent mixture that aids
in solubilization of SD without the need to use an aqueous
phase. Higher encapsulation efﬁciency was attained compared
with what we had obtained with encapsulation of sodium ﬂuo-
rescein (18.94 ± 0.01–25.70 ± 0.09%) with PGA-co-PDL
using spray drying from w/o/w multiple emulsion (Tawfeek
et al., 2011). However, 100% encapsulation efﬁciency cannot
be achieved due to some partitioning still occurring which
could be attributed to the miscibility of methanol with water.
The negative surface charge demonstrated the anionic nat-
ure of the produced microparticles, which may be associated
with incomplete removal of PVA present in the external aque-
ous phase of the single emulsion. It is accepted that spray dry-
ing products are mainly characterized by their amorphous
nature or the disordered crystalline phase due to rapid drying
of droplets (Corrigan, 1995). This behavior was demonstrated
in our study by the broadening of the melting endothermic
peaks for spray-dried formulations. Furthermore, the accumu-
lation of L-leucine at the air–liquid interface and the surface of
microparticles may contribute to enhance broadening of the
endothermic melting peak compared with untreated polymers
(control). Similar results were also found in our previous work
using PGA-co-PDL and different amino-acids as dispersibility
enhancers (Tawfeek et al., 2011). In addition, the shift of endo-
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height) indicated distribution of the drug inside the PEG-
PGA-co-PDL-PEG and PGA-co-PDL-PEGme microparticles.
The geometric particle size, particle shape and morphology
are known to affect the aerodynamic properties and pulmon-
ary deposition (Bean et al., 1967). The dae calculated from
tapped density indicated the spray-dried particles generated
are suitable for targeting the alveolar region. However,
in vitro aerosolization results suggested that the formulations
did not aerosolize as individual particles, but rather as particle
aggregates, as indicated when comparing geometric particle
size with MMAD. This most likely occurred due to an incom-
plete powder de-aggregation as van der Waals forces between
particles were not completely overcome upon inhalation. The
wrinkled morphology of the produced microparticles has been
observed by many researchers (Seville et al., 2007). The reason
for that behavior is possibly due to the excessive built up of va-
por pressure during solvent evaporation in the spray drying
process especially with hydrophobic amino acids, such as L-
leucine (Alder et al., 2000). It was worth noting that, leucine
not only acts as a dispersibility enhancer but it also affects
the in vitro release of SD from the prepared microparticles.
Once again, this could be attributed to the surface activity of
L-leucine coating the microparticles during the spray drying
process. Hence reduced surface adsorption of the drug, de-
creased the continuous release especially marked with hydro-
phobic PGA-co-PDL. Similar results have been reported for
L-leucine and sodium ﬂuorescein loaded PGA-co-PDL micro-
particles (Tawfeek et al., 2011). Also this behavior was found
with other surfactants, such as polysorbate 20 and sodium
dodecyl sulfate, which reduced the surface accumulation of
certain proteins in a concentration-dependant manner (Alder
et al., 2000; Maa et al., 1998). However, the higher burst re-
lease of SD associated with PEG-PGA-co-PDL-PEG and
PGA-co-PDL-PEGme microparticles may be due to the
migration of some drug crystals toward the microparticle
surface by residual solvent during the spray drying process.
Furthermore, the higher amounts of SD released from PEG-
PGA-co-PDL-PEG and PGA-co-PDL-PEGme compared to
PGA-co-PDL could be attributed to the presence of either
PEG or mPEG within the polymer backbone which affected
the polymer matrix and hydrophobicity. Additionally, it can
also inﬂuence its plasticity and porosity (Jiang et al., 2002;
Chew et al., 2005b), resulting in more rapid entry of water into
the microparticles, eventually accelerating the release of the
drug (Castellanos et al., 2005). Also, we cannot neglect the ef-
fect of polymer Mwt, hence PEG-PGA-co-PDL-PEG and
PGA-co-PDL-PEGme have a lower Mwt (13.6, 7.6 KDa,
respectively, compared to PGA-co-PDL, 21.0 KDa).
In this current investigation, the release of SD from differ-
ent formulations followed Higuchi’s model, and mediated
through the diffusion process with very little contribution to
the degradation of the polymer. Whether drug release is gov-
erned primarily via diffusion or degradation depends on
whether drug dissolution/diffusion or polymer degradation is
faster (Hillery et al., 2001). Hence, to achieve zero-order re-
lease, it is recommended that the rate of polymer degradation
controls the rate of release (Go¨pferich, 1996; Edlund and
Albertsson 2002). Degradable microparticles do not give zero
order release because a constant surface area for drug release
cannot be maintained due to the degradation of the rate con-
trolling membrane. It should not be possible to get zero-orderrelease from degradable microparticles unless they have sur-
face-only erosion because, in order for the drug path length
to stay constant, zero order release requires the microparticles
to degrade from the outside (Tice and Cowsar, 1984). This
means that, in order to be released, the drug at the center of
the microparticles should have the same distance to travel as
the drug near the surface, assuming that the drug is homoge-
neously dispersed within the matrix (Leach, 1999). Addition-
ally the incomplete release of SD from the prepared
microparticles may be associated with the slow hydrolyzation
of the ester linkages in the polymer backbone (Thompson
et al., 2008) especially with PGA-co-PDL microparticles hav-
ing a very stable ester linkage between monomers. So, further
investigations are required to optimize the release proﬁle by
making a di-or tri-block PEGylated co-polymer or by attach-
ing the PEG molecules to the hydroxyl group of glycerol
subunit.
Recently, the addition of various dispersing agents such as,
L-arginine and L-leucine amino acids, as potential dispersibility
enhancers to improve the aerosol performance was investi-
gated (Li et al., 1996, 2005; Seville et al., 2007; Tawfeek
et al., 2011). Also L-leucine was found to be superior to any
other investigated amino acids in enhancing the aerosolization
performance of PGA-co-PDL loaded sodium ﬂuorescein
microparticles (Tawfeek et al., 2011). Thus all formulations
were prepared utilizing L-leucine (1.5% w/w of polymer
weight). Moreover, higher amounts of powder deposited in
the throat, this possibly attributed to the aerosolization condi-
tions (ﬂow rate 60 L/min, HandiHaler) that cannot over-
come the Van der Waal forces between particles. Also, some
aggregation of microparticles, especially those prepared using
PGA-co-PDL and PEG-PGA-co-PDL-PEG, was noticed and
demonstrated through the lower values of FPD and FPF%
(Table 2). The higher throat deposition could also be attrib-
uted to the higher strength of Van der Waals forces. These
forces are directly proportional to the contact surface area of
a particle; hence, an increase in Van der Waals forces strength
is observed with small particle size (Table 2) due to their larger
surface area. Furthermore, all the investigated carriers show a
higher deposition on different stages of NGI as seen in Fig. 7
due to the coating effect of L-leucine together with lower
tapped density and water content values. In addition to the en-
hanced physical stability of microparticles presented in rela-
tively higher zeta potential values (Table 1), all of these
factors can improve the aerosolization performance. More-
over, PGA-co-PDL-PEGme spray dried microparticles would
be expected to perform well during inhalation and to deliver
a large proportion of the dose to the central and even periph-
eral regions of the lungs due to the higher amounts deposited
on lower stages of NGI, 6–8 (Cut off diameter, 0.57–0.13 lm).
The lower value of MMAD (2.92 ± 0.17 lm), higher FPD
(33.39 ± 0.58) and FPF% (44.06 ± 0.17) might be responsible
for this optimum deposition. Furthermore, the enhanced
hydrophilic characters of PEG and mPEG containing poly-
mers compared to the hydrophobic PGA-co-PDL generated
particles with a higher deposition in lower stages of NGI,
hence, they can be used as successful carriers for lung periph-
ery. However, the safety of the carrier used for pulmonary
drug delivery is an important issue. Normal bronchial epithe-
lial cells (16HBE14o-) were chosen in accordance with the
aerosolization and particle size distribution (MMAD) results
for the particles generated (Canal-Rafﬁn et al., 2007). The
396 H.M. Tawfeekhigher% cell viability and good cells tolerability observed from
different carriers even at higher microparticle concentration
(5 mg/ml) provide an indication about the feasibility of using
PEG-PGA-co-PDL-PEG and PGA-co-PDL-PEGme as alter-
native safe sustained release carriers for pulmonary drug deliv-
ery. This higher microparticle concentration (5 mg/ml) cannot
be found in the lung in our study. However, it was prepared
and used to show that even higher concentrations of micropar-
ticles, generated using a different technique or more advanced
inhaler, reached into the lung still safe and tolerated.
5. Conclusion
The present study suggests that PEG-PGA-co-PDL-PEG and
PGA-co-PDL-PEGme could be considered as alternative novel
biodegradable sustained release carriers for lung delivery. They
showed an enhanced encapsulation efﬁciency and lower hydro-
phobicity. Furthermore, they have the ability to enhance the re-
lease of SD from the prepared microparticles compared to
PGA-co-PDL microparticles. Utilizing lipase enzyme from
Candida antarctica successfully produced the PEG and mPEG
containing polymers within higher yields and lower surface con-
tact angle (h) compared to PGA-co-PDL hence, an optimum
deposition on lung periphery was obtained from NGI data.
In addition, incorporation of L-leucine was found to enhance
the aerosolization performance and decrease the continuous re-
lease of SD from different used carriers. PGA-co-PDL-PEGme
has the ability to deliver higher amounts of SD to the central
and peripheral regions of the lungs. Furthermore, cell viability
study revealed the safety of PEG-PGA-co-PDL-PEG and
PGA-co-PDL-PEGme spray dried microparticles. Future stud-
ies will be conducted to determine if the polymers elicit an im-
mune response and the drug transport through different lung
cell lines e.g., calu-3 cell lines. In addition, we will investigate
the possibility of making nanoparticles to enhance the aerosol-
ization performance and interaction with the lung cells.Acknowledgments
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